ReviewFrontiers in pharmacology2026
Recent advances in phosphoproteomics based on mass spectrometry and its clinical application prospects.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein phosphorylation, a key post-translational modification, plays a crucial role in regulating cellular activities in eukaryotes. Dysregulation of phosphorylation is closely linked to the pathogenesis of various diseases Recent advancements in phosphoproteomics have driven substantial improvements in mass spectrometry technologies, enrichment strategies, and data analysis methodologies, thereby offering a powerful and precise tool for elucidating the spatiotemporal dynamics of phosphorylation events. Nevertheless, several challenges remain, such as the limited sensitivity for detecting low-abundance signals, throughput constraints of single-cell technologies, and the absence of standardized workflows, all of which impede clinical translation. Moving forward, AI-driven experimental design, spatial omics coupling, and interdisciplinary technological integration will drive the transition of phosphoproteomics from basic research to precision medicine, providing novel insights for disease diagnosis and treatment. This review aims to comprehensively summarize recent technological developments and future trends in phosphoproteomics, focusing on its clinical translation potential and associated challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.